The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacological Reports

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 16415488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Parecoxib (Parecoxib Sodium)

  2012cited by this paper
• Valdecoxib

  2012cited by this paper
• Etoricoxib

  2012cited by this paper
• Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

  2006cited by this paper
• Prostacyclin protects against elevated blood pressure and cardiac fibrosis.

  2005cited by this paper
• Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis

  2005cited by this paper
• COX-2–Derived Prostacyclin Modulates Vascular Remodeling

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Cardiovascular hazard and non-steroidal anti-inflammatory drugs.

  2005cited by this paper
• Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.

  2005cited by this paper
• Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

  2005cited by this paper
• Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism

  2005cited by this paper
• Parecoxib, valdecoxib, and cardiovascular risk.

  2005cited by this paper
• The safety of lumiracoxib when used in the treatment of arthritis

  2005cited by this paper
• Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene.

  2005cited by this paper
• Effects of estrogen with and without progestin on urinary incontinence

  2005cited by this paper
• Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

  2005cited by this paper
• Selective cyclooxygenase 2 inhibitors and cardiovascular events.

  2005cited by this paper
• Clinical pharmacology of etoricoxib

  2005cited by this paper
• Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

  2004cited by this paper
• COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice

  2004cited by this paper
• Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects

  2004cited by this paper
• Pharmaceutical Exploitation: Cyclooxygenase and Lipoxygenase Inhibitors

  2004influential reference
• Valdecoxib of its Use in the Management of Osteoarthritis, Rheumatoid Arthritis, Dysmenorrhoea and Acute Pain

  2004cited by this paper
• Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice

  2004cited by this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

  2004cited by this paper
• Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway.

  2004cited by this paper
• Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.

  2004cited by this paper
• Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients

  2004cited by this paper
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

  2004cited by this paper
• Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

  2004cited by this paper
• Clinical pharmacology of novel selective COX-2 inhibitors.

  2004cited by this paper
• The structure of mammalian cyclooxygenases.

  2003cited by this paper
• COX-2 and beyond: approaches to prostaglandin inhibition in human disease

  2003cited by this paper
• Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

  2003cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• Effect of ibuprofen on cardioprotective effect of aspirin.

  2003cited by this paper
• COX-3: in the wrong frame in mind.

  2003cited by this paper
• Platelets in Thrombotic and Nonthrombotic Disorders

  2003cited by this paper
• Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial.

  2003cited by this paper
• COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells.

  2003cited by this paper
• Cellular Prostaglandin E2 Production by Membrane-bound Prostaglandin E Synthase-2 via Both Cyclooxygenases-1 and -2*

  2003influential reference
• Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor

  2003cited by this paper
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2002cited by this paper
• Thromboxane synthase: structure and function of protein and gene.

  2002cited by this paper
• Coordinate regulation of prostaglandin metabolism for induction of parturition in mice.

  2002cited by this paper
• Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

  2002cited by this paper
• The Assembly and Intermolecular Properties of the hsp70-Hop-hsp90 Molecular Chaperone Complex*

  2002cited by this paper
• COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression

  2002influential reference
• Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II.

  2002cited by this paper
• Identification and characterization of a novel type of membrane-associated prostaglandin E synthase.

  2002cited by this paper
• The enzymology of prostaglandin endoperoxide H synthases-1 and -2.

  2002cited by this paper
• Cyclic mechanical stretch augments prostacyclin production in cultured human uterine myometrial cells from pregnant women: possible involvement of up-regulation of prostacyclin synthase expression.

  2002cited by this paper
• The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity

  2002cited by this paper
• Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence.

  2002cited by this paper
• Prostaglandin F synthase.

  2002cited by this paper
• Platelets in Thrombotic and Non-thrombotic Disorders: Amplification loops: thromboxane generation

  2002cited by this paper
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2001cited by this paper
• Regulated formation of eicosanoids.

  2001cited by this paper
• Genetic and pharmacological analysis of prostanoid receptor function.

  2001influential reference
• Physiological regulation of cyclooxygenase-2 in the kidney.

  2001cited by this paper
• Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.

  2001influential reference
• Coupling between Cyclooxygenase, Terminal Prostanoid Synthase, and Phospholipase A2 *

  2001cited by this paper
• Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.

  2001cited by this paper
• Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2

  2001cited by this paper
• A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

  2001cited by this paper
• Microsomal Prostaglandin E Synthase Is Regulated by Proinflammatory Cytokines and Glucocorticoids in Primary Rheumatoid Synovial Cells1

  2001cited by this paper
• Why there are two cyclooxygenase isozymes.

  2001cited by this paper
• Molecular cloning and induction of bovine prostaglandin E synthase by gonadotropins in ovarian follicles prior to ovulation in vivo.

  2001cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001influential reference
• Cloning, Expression, and Up-regulation of Inducible Rat Prostaglandin E Synthase during Lipopolysaccharide-induced Pyresis and Adjuvant-induced Arthritis*

  2001cited by this paper
• Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes.

  2001cited by this paper
• Molecular Cloning and Induction of Bovine Prostaglandin E Synthase by Gonadotropins in Ovarian Follicles Prior to Ovulationin Vivo *

  2001cited by this paper
• Lipocalins as biochemical markers of disease.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2*

  2000cited by this paper
• Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2Biosynthesis*

  2000influential reference
• Crystal Structure and Activity of Human p23, a Heat Shock Protein 90 Co-chaperone*

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Identification of Mu-Class Glutathione Transferases M2-2 and M3-3 as Cytosolic Prostaglandin E Synthases in the Human Brain

  2000cited by this paper
• Distribution and function of prostanoid receptors: studies from knockout mice.

  2000cited by this paper
• Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor

  1999cited by this paper
• Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.

  1999cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

  1999cited by this paper
• Cyclooxygenase-2 expression and function in the medullary thick ascending limb.

  1999cited by this paper
• Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development.

  1999cited by this paper
• Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet.

  1998cited by this paper
• Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

  1997cited by this paper
• Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

  1997cited by this paper
• COX-1 and COX-2 tissue expression: implications and predictions.

  1997cited by this paper
• Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

  1996cited by this paper
• Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

  1996cited by this paper
• Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress.

  1996cited by this paper
• Arginine 120 of Prostaglandin G/H Synthase-1 Is Required for the Inhibition by Nonsteroidal Anti-inflammatory Drugs Containing a Carboxylic Acid Moiety *

  1995cited by this paper
• In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs

  1995cited by this paper

• Inhibitory effects of NSAID-conjugated SN-38 on the viability of A549 Non-small cell lung cancer cells

  2023cites this paper
• Diclofenac exhibits cytotoxic activity associated with metabolic alterations and p53 induction in ESCC cell lines and decreases ESCC tumor burden in vivo.

  2023cites this paper
• Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?

  2023cites this paper
• Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials

  2022cites this paper
• Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo

  2020cites this paper
• Raging the War Against Inflammation With Natural Products

  2018cites this paper
• Pain Management : A systematic review

  2017cites this paper
• 7‐Chloro‐4‐phenylsulfonyl quinoline, a new antinociceptive and anti‐inflammatory molecule: Structural improvement of a quinoline derivate with pharmacological activity

  2017cites this paper
• Celecoxib prevents pressure overload‐induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress

  2015cites this paper
• Cyclooxygenase inhibitors: From pharmacology to clinical read-outs.

  2015cites this paper
• Molecular mechanisms of inflammation – a central role for cytosolic phospholipase A2

  2014cites this paper
• Pharmacological Neuroprotection for Acute Spinal Cord Injury

  2014cites this paper
• Management of Hyperuricemia and Gout

  2013cites this paper
• Celecoxib

  2012cites this paper
• Recent Advances in the Pharmacological Management of Pain

  2012cites this paper
• A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.

  2011cites this paper
• Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.

  2010cites this paper
• Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events

  2010cites this paper
• Pharmacological neuroprotective therapy for acute spinal cord injury: state of the art.

  2008cites this paper
• Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs

  2008cites this paper
• Aproximación A. Evidencias a favor de la prescripción de los inhibidores selectivos de la COX-2

  2008cites this paper
• Risk management profile of etoricoxib: an example of personalized medicine

  2008cites this paper
• Effects of etoricoxib on the pharmacokinetics of phenytoin.

  2008cites this paper
• Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin.

  2007cites this paper
• Synthesis, characterization and preliminary screening of regioisomeric 1-(3-pyridazinyl)-3-arylpyrazole and 1-(3-pyridazinyl)-5-arylpyrazole derivatives towards cyclooxygenase inhibition

  2007cites this paper
• Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.

  2007cites this paper
• Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations.

  2007cites this paper
• Growth inhibition effect of DL-lysine acetylalicylate on sw480 colon carcinoma cells

  2007cites this paper
• How to advise aspirin use in patients who need NSAIDs.

  2007cites this paper
• Are there any Differences among Non-Steroidal Anti-Inflammatory Drugs? Focus on Nimesulide

  2007cites this paper
• Pharmacotherapy in orthodontic treatment supported by micro-implants

  2007cites this paper
• Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: a randomized, double-blind, placebo-controlled study.

  2006cites this paper
• Do selective COX‐2 inhibitors increase the risk of cerebrovascular events? A meta‐analysis of randomized controlled trials

  2006influential citation